Cover Image
市場調查報告書

全球大腸癌症診斷、治療藥市場 (各診斷、技術、地區) :預測 (2015年∼2020年)

Global Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends & Forecast (2017 - 2022)

出版商 Mordor Intelligence LLP 商品編碼 353905
出版日期 內容資訊 英文 205 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球大腸癌症診斷、治療藥市場 (各診斷、技術、地區) :預測 (2015年∼2020年) Global Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends & Forecast (2017 - 2022)
出版日期: 2017年01月24日 內容資訊: 英文 205 Pages
簡介

全球大腸癌症診斷、治療藥市場,預計2015年∼2020年以1∼5%的年複合成長率成長。

本報告提供全球大腸癌症診斷、治療藥市場相關調查分析,市場概要,推動市場要素、阻礙因素、機會,各市場區隔的市場分析,競爭情形,主要企業等,有系統的資訊。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義
  • 推動市場要素
  • 阻礙市場要素
  • 市場機會

第4章 波特的五力分析

第5章 市場區隔

  • 各診斷
  • 各治療
  • 各地區

第6章 競爭情形

  • M&A
  • 契約、夥伴關係、聯盟
  • 新產品的銷售
  • 建議

第7章 企業簡介

  • Abbott Diagnostics
  • Alere
  • Beckman Coulter
  • Clinical Genomic
  • Companion Dx
  • EDP Biotech
  • Epigenomics AG
  • Exact Sciences
  • FUJIREBIO
  • Genomic Tree
  • Metabiomics
  • Oncocyte (Biotime)
  • Quest Diagnostics
  • Randox Laboratories
  • Siemens Healthcare
  • Volition Rx

第8章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Description

The global colorectal cancer diagnostics and therapeutics market is expected to grow at a CAGR of around 6% during the forecast period 2016-2021. The market is estimated to be valued at USD 8000 million in 2015 and is forecasted to reach USD 10,706 million by 2021.

The CRC pipeline is highly robust, with many potential drug candidates present across various phases of clinical development. With nearly 400 active pipeline molecules, a majority of the investigational drug candidates are being evaluated for the treatment of CRC in advanced stages, either as first-line or as second-line therapies. The current investigational pipeline candidates include new combination therapies and targeted therapies, as well as, promising immunotherapies and chemotherapy drug candidates. Along with these active progressing pipeline molecules, the pipeline also includes nearly 180 molecules that are either inactive or discontinued.

Global Colorectal Cancer Diagnostics and Therapeutics - Market Dynamics

The report details several factors driving and restraining the market, some of which are discussed below.

Drivers

Technological advancements in cancer therapy

Aging population

Increasing consumer awareness

Restraints

High costs of screening tests

Patent expiry of existing drugs

The global cancer diagnostics and therapeutics market has been segmented by diagnostics (fecal blood tests, flexible sigmoidoscopy, colonoscopy, virtual colonoscopy, double contrast barium enema, and others), and by therapeutics (chemotherapy, immunotherapy, and chemoprotectants). Chemotherapy has been further segmented into antimetabolites (fluorouracil and capecitabine) and alkylating agents; and immunotherapy has been further segmented into bevacizumab, cetuximab, and panitumumab. The market has been geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World.

Some of the key players in the market are:

Abbott Diagnostics

Alere

Beckman Coulter

Clinical Genomics

Metabiomics Corporation

What the Report Offers

Market definition, along with identification of key drivers and restraints for the market.

Market analysis with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.

An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.

Table of Contents

1. Introduction

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Research Methodology

2. Market definition

3. Executive summary

4. Market overview

  • 4.1 Market drivers
    • 4.1.1 Technological Advancements in Radiology and Chemotherapy
    • 4.1.2 Aging Population
    • 4.1.3 Increasing Consumer Awareness
  • 4.2 Market restraints
    • 4.2.1 Expiry of Drug Patents
    • 4.2.2 Screening test costs
  • 4.3 Market opportunities
    • 4.3.1 Highly Robust Product Pipeline
  • 4.4 Market Challenges
    • 4.4.1 Less Awareness and Practice of Cancer Screening Tests in Developing Countries

5. Porters five force analysis

  • 5.1 Bargaining power of suppliers
  • 5.2 Bargaining power of buyers
  • 5.3 Degree of comprtition
  • 5.4 Threat of substitution
  • 5.5 Threat of new entrants

6. Market segmentation

  • 6.1 By Diagnostics
    • 6.1.1 Digital Rectal Examination
    • 6.1.2 Fecal Occult Blood Test
    • 6.1.3 Flexible Sigmoidoscopy
    • 6.1.4 Colonoscopy
    • 6.1.5 Virtual Colonoscopy
    • 6.1.6 Double Contrast Barium Enema
    • 6.1.7 Others
  • 6.2 By Therapeutics
    • 6.2.1 Chemotherapy
      • 6.2.1.1 Antimetabolites
      • 6.2.1.1.1 Fluorouracil
      • 6.2.1.1.2 Capecitabine
      • 6.2.1.2 Alkylating Agent
    • 6.2.2 Immunotherapy
      • 6.2.2.1 Monoclonal Antibodies
      • 6.2.2.1.1 Bevacizumab
      • 6.2.2.1.2 Cetuximab
      • 6.2.2.1.3 Panitumumab
    • 6.2.3 Chemoprotectant
  • 6.3 By geography
    • 6.3.1 North America
      • 6.3.1.1 United States
      • 6.3.1.2 Canada
      • 6.3.1.3 Mexico
    • 6.3.2 Europe
      • 6.3.2.1 France
      • 6.3.2.2 Germany
      • 6.3.2.3 Italy
      • 6.3.2.4 Spain
      • 6.3.2.5 United Kingdom
      • 6.3.2.6 Rest of Europe
    • 6.3.3 Asia-Pacific
      • 6.3.3.1 China
      • 6.3.3.2 India
      • 6.3.3.3 Japan
      • 6.3.3.4 Korea
      • 6.3.3.5 Singapore
      • 6.3.3.6 Rest of APAC
    • 6.3.4 Rest of the world

7. Competitive Landscape

  • 7.1 Mergers & Acquisitions
  • 7.2 Agreements, Partnerships and Collaborations
  • 7.3 New Product Launches

8. Company profiles

  • 8.1 Abbott Diagnostics
  • 8.2 Alere
  • 8.3 Beckman Coulter
  • 8.4 Clinical Genomics
  • 8.5 Companion Dx
  • 8.6 EDP Biotech
  • 8.7 Epigenomics AG
  • 8.8 Exact Sciences
  • 8.9 Fujirebio (Miraca Holdings)
  • 8.10 Genomic Tree
  • 8.11 Metabiomics Corporation
  • 8.12 Oncocyte (Biotime)
  • 8.13 Quest Diagnostics
  • 8.14 Randox Laboratories
  • 8.15 Siemens Healthcare
  • 8.16 Volition Rx

9. Appendix

  • 9.1 Abbreviations
  • 9.2 Sources
  • 9.3 Bibliography
  • 9.4 Disclaimer
Back to Top